The construct can not only be effectively taken up by DCs and promote their maturation but also result in a CD8+ T cell response against B16-OVA tumor cells in vitro. Moreover, the vaccine significantly increased the recruitment of CD8+ and CD4+ T cells and inhibited tumor growth in tumor-bearing mice [160]. This evidence concerns the gene CD8A and neoplasm.